Metotreksat veya diğer geleneksel hastalık modifiye edici anti-romatizmal tedavilere yetersiz yanıt veren Romatoid Artrit hastalarında biyolojikler veya Tofasitinib: Bir Sistematik Derleme ve Network Meta-analizi
Cochrane Database of Systematic Reviews 2016 Issue 5. Art. No.: CD012183 [DOI: 10.1002/14651858.CD012183].
Treatment options for RA patients who are MTX/DMARD incomplete responders (IR) include other DMARDs, biologics or tofacitinib (TOF). However, there is a lack of head-to-head studies to show any important differences between these options in terms of benefits and harms. This review provides an update of the 2009 Cochrane overview and network meta-analysis (NMA) of biologics for RA.1Nine biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, a...